Compare ARRY & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARRY | VTYX |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 990.9M |
| IPO Year | 2020 | 2021 |
| Metric | ARRY | VTYX |
|---|---|---|
| Price | $6.93 | $13.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 7 |
| Target Price | $10.24 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 6.6M | 3.8M |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.56 | 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,141,000.00 | N/A |
| Revenue This Year | $16.03 | N/A |
| Revenue Next Year | $7.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.22 | N/A |
| 52 Week Low | $3.76 | $0.90 |
| 52 Week High | $12.23 | $15.34 |
| Indicator | ARRY | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 72.58 |
| Support Level | $6.47 | $13.89 |
| Resistance Level | $10.02 | $14.07 |
| Average True Range (ATR) | 0.56 | 0.03 |
| MACD | -0.16 | -0.11 |
| Stochastic Oscillator | 7.54 | 88.89 |
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.